[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

GSK plc (GSK)

GSK's Blujepa receives FDA approval for gonorrhea treatment, while the company terminates a collaboration with Ideaya Biosciences, returning rights to two clinical-stage assets.

About GSK plc

GSK plc is a multinational pharmaceutical and biotechnology company.
GSK plc uses the ticker $GSK for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

GSK plc (GSK) trading volume is up XXXXX% from the previous week.
GSK plc (GSK) social dominance is up XXXXXX% from the previous week.
GSK plc (GSK) Galaxy Score™ is up XXXXXX% from the previous X months.

Price: $XXXXX

Price 24-Hour Time-Series Raw Data
GSK's stock price is near a 52-week high, supported by positive sentiment from FDA approvals and social media engagement, but recent legal disputes and concerns over Blenrep's label restrictions may introduce volatility.

24-Hour: XXX% 7-Day: XXXX% 30-Day: XXXX%

1-Year High: $XX on 2025-12-03
1-Year Low: $XXXXX on 2025-01-14

AltRank: XXXXX

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
GSK plc (GSK) is currently AltRank #1,020 based on combined combined social and market metrics Daily Average: XXX
X Week: XXX -XXX
X Month: XXX -XXX
X Months: XXX -XXXXX
X Year: XXX -XX
1-Year High: XXXXX on 2025-06-19
1-Year Low: X on 2025-02-09

Galaxy Score: XXXXX

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX +15
X Month: XX +22
X Months: XX +26
X Year: XX +27
1-Year High: XX on 2025-05-13
1-Year Low: XX on 2025-07-03

Engagements: XXXXXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXX
Daily Average: XXXXXX
X Week: XXXXXX -XX%
X Month: XXXXXXX -XX%
X Months: XXXXXXXXX +30%
X Year: XXXXXXXXX -XX%
1-Year High: XXXXXXX on 2025-02-05
1-Year Low: XXX on 2025-12-07

Engagements by network (24h): Reddit: XX X: XXXXXX YouTube: XX

Mentions: XX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXX -XX%
X Months: XXXXX +74%
X Year: XXXXX +73%
1-Year High: XXX on 2025-08-03
1-Year Low: XX on 2025-12-07

Mentions by network (24h): Reddit: X X: XXX YouTube: X

Creators: XX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning GSK plc (GSK) in the last XX hours which is up XX% from XX in the previous XX hours Daily Average: XX
X Week: XX -XX%
X Month: XXX -XX%
X Months: XXXXX +73%
X Year: XXXXX +63%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-12-07

The most influential creators that mention GSK plc in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@BiopharmIQ	X	XXXXXX	X	XXXXX
@learnbiotech	X	XXXXX	X	XXXXX
@tradingfloorai	X	XXXXX	X	XX
@theflynews	X	XXXXXX	X	XX
@MoneyMaker0009	X	XXX	X	XX
@BioSignal	X	XX	X	XX
@Darwin_Knows	X	XXX	X	XX
@MarcJacksonLA	X	XXXXX	X	XX
@fastmoneysource	X	XXX	X	X
@linhnguyen64143	XX	XX	X	X

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -XX%
X Month: XX% -XX%
X Months: XX% -XX%
X Year: XX% -XX%
1-Year High: XXX% on 2025-04-21
1-Year Low: XX% on 2025-08-26

Most Supportive Themes:

FDA Approval of Blenrep: (30%) GSK's multiple myeloma drug Blenrep has received FDA approval for specific patient groups, marking a significant regulatory milestone.
Earnings Reports and Financial Performance: (25%) GSK's recent earnings reports and financial performance are being closely watched and discussed, with revenue and EPS figures highlighted.
Partnerships and Acquisitions: (20%) GSK is actively engaging in strategic partnerships and acquisitions, such as the deal with Empirico, to expand its pipeline and market reach.

Most Critical Themes:

Blenrep Label Restrictions: (40%) Despite FDA approval, Blenrep's label is narrower than anticipated, raising concerns about its near-term commercial upside and market penetration.
Pipeline Development Challenges: (35%) GSK faces ongoing challenges in its R&D pipeline, with some drug candidates like the one partnered with Alector failing in late-stage trials.

Social Dominance: XXXXXXX%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.019%
X Month: XXXXXX% -XXXXX%
X Months: XXXXXX% -XXXXXX%
X Year: XXXXXX% -XXXXX%
1-Year High: XXXXX% on 2025-01-02
1-Year Low: XXXXXX% on 2025-12-07

Market Dominance: XXXXX%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: X%
1-Year High: XXXX% on 2025-12-02
1-Year Low: XXXXX% on 2025-12-12

Market Cap: $XXXXXXXXXXXXXX

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXXX +$0.75%
X Month: $XXXXXXXXXXXXXX +$2%
X Months: $XXXXXXXXXXXXXX +$19%
X Year: $XXXXXXXXXXXXXX +$41%
1-Year High: $XXXXXXXXXXXXXX on 2025-12-03
1-Year Low: $XXXXXXXXXXXXXX on 2025-01-14